Investigating Mycobacterium abscessus to inform treatment and drug discovery


The environmental non-tuberculous mycobacteria, Mycobacterium abscessus, is quickly becoming a major health concern in developed countries in part to its extensive multi-drug resistance. Those at risk of contracting M. abscessus lung disease are primarily people who are immunocompromised or have pre-existing lung disorders such as Cystic Fibrosis. Treatment for this disease involves a lengthy regimen of several antibiotics, despite this, treatment failure rates remain unacceptably high. The background of this infectious disease, its clinical manifestation and management is discussed in detail in Chapter 1. The first results chapter of this thesis, chapter 2, makes use of genomic techniques to explore the subspecies of a panel of M. abscessus clinical isolates, alongside their drug susceptibility patterns, in order to elucidate a link between M. abscessus subspecies (M. abscessus subsp. abscessus, M. abscessus subsp. bolletii, and M. abscessus subsp. massiliense) and drug resistance. Given the high levels of treatment failure, it is essential to find new treatments for M. abscessus infections, that can be introduced into clinical practice in the near future. Chapter 3 of this thesis explores the repurposing of a new and approved β-lactamase inhibitor, relebactam, for inclusion into the M. abscessus chemotherapeutic regimen. Here, relebactam’s efficacy against the endogenous M. abscessus β-lactamase, BlaMab is discovered, as well as its inhibitory activity when combined with the carbapenem, imipenem. This activity is further potentiated with by the addition of amoxicillin. This three-drug combination has widespread activity against a panel of clinical isolates, within a therapeutically achievable concentration range. Finally, an in vitro model of persistence in M. abscessus infection was developed and this was used to assess frontline drug susceptibilities, providing an insight into the possible causes of treatment failure for this infection. Overall, this body of work contributes to the knowledge of the organism, provides a greater understanding of the clinical challenge it represents and proposes a new treatment option for patients suffering with this deadly infection.

Divisions: Aston University (General)
Additional Information: © Rose Claire Lopeman, 2021. Rose Claire Lopeman asserts their moral right to be identified as the author of this thesis. This copy of the thesis has been supplied on condition that anyone who consults it is understood to recognise that its copyright rests with its author and that no quotation from the thesis and no information derived from it may be published without appropriate permission or acknowledgement. If you have discovered material in Aston Publications Explorer which is unlawful e.g. breaches copyright, (either yours or that of a third party) or any other law, including but not limited to those relating to patent, trademark, confidentiality, data protection, obscenity, defamation, libel, then please read our Takedown Policy and contact the service immediately.
Institution: Aston University
Last Modified: 08 Dec 2023 08:59
Date Deposited: 16 Mar 2022 17:25
Completed Date: 2021-02
Authors: Lopeman, Rose Claire

Export / Share Citation


Additional statistics for this record